Download Files:
Products Details
Product Description
– ATP Synthesis-IN-3 (compound 31) is an ATP hydrolysis inhibitor with protective effects during myocardial ischemia. ATP Synthesis-IN-3 can increase the ATP content of ischemic cardiomyocytes, increase the phosphorylation of PKA and phospholamban, and inhibit ischemia-induced apoptosis[1].
Web ID
– HY-149736
Shipping
– Room temperature
Molecular Formula
– C35H39N7O2
References
– [1]Nikolaou PE et al. Hydrolytic Activity of Mitochondrial F1FO-ATP Synthase as a Target for Myocardial Ischemia-Reperfusion Injury: Discovery and In Vitro and In Vivo Evaluation of Novel Inhibitors. J Med Chem. 2023 Nov 23;66(22):15115-15140.
Molecular Weight
– 589.73
SMILES
– CN1CCN(C2=CC=C(NC3=NC(N4CCOCC4)=C5C(C(C6=CC=CC=C6)=NN5CC7=CC=C(C=C7)OC)=C3)C=C2)CC1
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– ATP Synthase;PKA
Pathway
– Membrane Transporter/Ion Channel;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
